Niagen Bioscience Inc (NAGE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,771 | -5,388 | -4,420 | -11,662 | -7,895 |
| Depreciation Amortization | 331 | 258 | 270 | 344 | 399 |
| Accounts receivable | -874 | -882 | 1,345 | -1,217 | 278 |
| Accounts payable and accrued liabilities | 2,772 | 2,157 | -1,619 | 1,178 | 1,736 |
| Other Working Capital | -2,206 | -512 | -714 | -1,507 | 295 |
| Other Operating Activity | 636 | 1,786 | 1,231 | 2,744 | 1,089 |
| Operating Cash Flow | $-2,111 | $-2,580 | $-3,906 | $-10,120 | $-4,099 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -525 | -122 | 863 | -25 | -151 |
| Sale Of Investment | N/A | 1,842 | 225 | N/A | N/A |
| Purchase Sale Intangibles | -123 | -130 | -89 | -52 | -26 |
| Other Investing Activity | -123 | -130 | -89 | -52 | -26 |
| Investing Cash Flow | $-648 | $1,590 | $999 | $-77 | $-177 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 2,500 | 2,500 | N/A | N/A | N/A |
| Common Stock Issued | 2,070 | 467 | 4,757 | 10,390 | 2,551 |
| Common Stock Repurchased | N/A | N/A | N/A | -8 | N/A |
| Other Financing Activity | -226 | -274 | -108 | -86 | -82 |
| Financing Cash Flow | $4,344 | $2,694 | $4,649 | $10,296 | $2,469 |
| Beginning Cash Position | 3,965 | 2,261 | 520 | 420 | 2,227 |
| End Cash Position | 5,550 | 3,965 | 2,261 | 520 | 420 |
| Net Cash Flow | $1,585 | $1,703 | $1,741 | $100 | $-1,806 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,111 | -2,580 | -3,906 | -10,120 | -4,099 |
| Capital Expenditure | -525 | -123 | -137 | -25 | -151 |
| Free Cash Flow | -2,636 | -2,704 | -4,043 | -10,144 | -4,250 |